Sep 01,2021

Blue Note Therapeutics Announces New Collaboration for its Prescription Digital Therapeutic Candidate

Blue Note Therapeutics, a prescription digital therapeutics company singularly dedicated to serving patients experiencing cancer, today announced a new collaboration with Memorial Sloan Kettering Cancer Center (MSK) to help advance the development of the company’s prescription digital therapeutic (PDT) candidate to treat fear of cancer recurrence. The collaborators will come together under MSK’s Innovation Hub, a program that blends health tech innovators and MSK experts with the goal to speed the development of innovative products and businesses that have the potential to make a meaningful impact in the lives of people with cancer and their caregivers.

COLLABORATION PARTNERSHIP

#r&d

#pdt

View Analyst & Ambassador Comments
Go to original news
Mar 18,2021

Broward Health and Voluntis Launch a New Clinical Evaluation Program on Digital Therapeutics for Metastatic Breast Cancer

Voluntis, a leader in digital therapeutics, announced today a collaboration with Broward Health, a public health system in the U.S. The partnership will focus on conducting a real-world evaluation of Oleena®, a digital application that assists patients in managing their symptoms. As part of the collaboration, Oleena®, a FDA-authorized digital therapeutic application developed by Voluntis for patients with cancer, will be provided to patients with HR+/HER2- metastatic breast cancer to support them in self-managing symptoms and side effects of their conditions and treatments. The clinical research will start enrolling patients in 2021, following an initial deployment of Oleena at Broward Health North.

COLLABORATION PARTNERSHIP

#institution

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 27,2021

Voluntis and Eisai to collaborate on digital therapeutics for oncology patients

Voluntis, a leader in digital therapeutics, today announced a collaboration agreement with Eisai (Headquarters: Tokyo) to design and develop innovative digital therapeutics (DTx) to support patients treated for cancer as well as a strategic investment from Eisai in Voluntis. By leveraging Voluntis’ Theraxium technology platform, the two companies will collaborate on novel DTx specifically designed for patients and healthcare professionals to support cancer treatment. The partners’ goals are to jointly design and develop new DTx, and evaluate their benefits for patients, caregivers and healthcare professionals. Ultimately, the companies would collaborate on the commercialization of the DTx, once authorized for marketing by regulatory authorities. The new assets will be designed with the intent to be commercialized in the US, Japan and European markets.

COLLABORATION PARTNERSHIP

#r&d

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 01,2021

Blue Note Therapeutics and University of California Los Angeles Jonsson Comprehensive Cancer Center Commence a Single-Arm Open-Label Phase 2 Study for BNT001

Blue Note Therapeutics and the University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center have commenced a single-arm, open-label, Phase 2 study for BNT001. BNT001 is Blue Note’s lead prescription digital therapeutic (PDT) candidate for the treatment of symptoms of anxiety and depression related to cancer in adult patients. The investigator-initiated Phase 2 study will primarily assess the practical feasibility of integrating BNT001 into the care of stage I-III breast or lung cancer patients and evaluate patients’ acceptability of the product.

PRODUCT

#pdt

View Analyst & Ambassador Comments
Go to original news
May 12,2021

Voluntis receives CE Mark for new version of Oleena with expanded clinical intelligence

Voluntis, a leader in digital therapeutics, today announced that it has received the CE mark for a new version of Oleena featuring expanded clinical intelligence. Oleena is Voluntis’ proprietary digital therapeutic that supports patients in the self-management of their symptoms in combination with a wide range of cancer treatments, while allowing healthcare teams to remotely monitor the progress of the disease. It is based on the Theraxium platform developed by Voluntis, which also serves as the foundation for the digital therapeutics the company is co-developing with pharmaceutical partners.

REGULATORY CE MARK

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 01,2021

Blue Note Therapeutics Announces Recruitment for Registrational Clinical Trial Studying Effectiveness of Digital Medical Devices in Cancer Patients

Blue Note Therapeutics has announced recruitment for a registrational clinical trial (RCT) to study the effectiveness of two digital, software only, medical devices (SaMD). Both medical devices are anticipated to have an impact on mental and physical health when used adjunctively with multidisciplinary oncology care regimens. The RCT study population will consist of up to 553 patients living with stage I-III breast cancer or stage I-III non-small cell lung cancer. The study will seek to understand and evaluate the overall study outcomes, including impact on mental and physical health.

PRODUCT

#software

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 01,2021

Blue Note Explores the Impact of Technology on Cancer Care at the NCCN Virtual Policy Summit

On September 9, 2021, Laura Chavaree, head of patient engagement at Blue Note Therapeutics, joined other leading experts during the National Comprehensive Cancer Network (NCCN) Virtual Policy Summit: The Impact of Technology on Cancer Care in 2021. Access to Laura’s presentation, the full Summit recording and the NCCN press release here.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 27,2021

The 3rd generation of therapeutics is digital

With so many health issues stemming from lifestyle-related illnesses, it’s no surprise that one of the biggest aspects of the modern lifestyle may be part of the cure. Sidekick Health uses digital therapeutics (DTx), behavioral economics combined with artificial intelligence and gamification elements such as charity rewards to help patients adapt their behavior and stick to medical treatment plans—all on their smartphones.

PRODUCT

#mobile app

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jan 08,2021

Blue Note Therapeutics Partnering with Patient Advocacy Groups to Provide Digital Cancer-Related Mental Health Care During Pandemic

Working closely with leading cancer centers, community oncology clinics, and teams of patients, Blue Note is developing clinically validated prescription digital therapeutics (PDTs) to help reduce anxiety, depression, and other forms of cancer-related distress. COVID Cancer Care is a stress management program which uses cognitive behavioral therapy and relaxation therapy. Since launch, nearly 12,000 people across the United States have accessed the program, which is currently available through more than 20 nonprofit and advocacy organizations, including Cancer Support Community.

PRODUCT

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Apr 20,2021

Kaiku Health to develop digital patient monitoring for melanoma with leading global medicines company

Kaiku Health, the developer of digital health intervention platform in oncology, today announced it will develop digital patient monitoring and management for melanoma patients in collaboration with Novartis, a leading global medicines company. Kaiku Health and Novartis are now aiming to further improve the remote monitoring and support of these patients with the joint development of a therapy-specific module for patients receiving BRAF/MEK combination therapies for melanoma.

COLLABORATION PARTNERSHIP

#r&d

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY